New Weight-Loss pill enters human testing

NCT ID NCT07160400

Recruiting now Disease control Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety of a new oral drug, IBI3032, in 104 people. Part A gives a single dose to healthy volunteers, while Part B gives multiple doses over 4 weeks to people with overweight or obesity. The goal is to check for side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3032 (a GLP-1 receptor agonist tablet)
What this could lead to: If successful, this could lead to a new oral medication for weight management, offering an alternative to injectable treatments.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PART A: HEALTHY PART B: OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Zhongshan Hospital affiliated to Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.